Navigation Links
Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting

prosan 20 with carmustine implant, MGI Pharma), the first approved local therapy for glioma.

Derived from each individual's tumor, Oncophage contains the 'antigenic fingerprint' of the patient's particular cancer and is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. Oncophage is intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy. Oncophage has been granted fast track and orphan drug designations from the US Food and Drug Administration (FDA) in both metastatic melanoma and renal cell carcinoma.

Study Findings

The investigator-sponsored Phase 1/2 study is designed to evaluate the feasibility, safety and activity of Oncophage vaccination in patients with recurrent, high-grade glioma. The trial involves two cohorts of six patients, both receiving a minimum of four Oncophage injections: the first cohort receives biweekly vaccinations; the second cohort receives weekly vaccinations. Patients are monitored for immune response before and after Oncophage treatment using three different techniques.

According to investigators, no adverse events or toxicity identified were considered attributable to the vaccine. A tumor-specific immune response was detected after vaccination in all 12 patients. The investigators will continue to follow patients for overall survival. Researchers plan to present further results from the Phase 1/2 trial of Oncophage in late 2007 and submit the findings for peer-review publication. Based on these results, the Phase 2 portion of this study is expected to move forward in mid-2007.

"Our goal is to change the management of recurrent glioma from a life threatening disease, in which survival rates are typically 25 to 26 weeks, into a chronic disease with extended survival and improved quality of life for patients," said Dr. Parsa. "Alth
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
(Date:5/29/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... at the American Association of Cancer Research ... on the potential for its lead product candidate ...
(Date:5/29/2015)... INDIANAPOLIS , May 29, 2015  Eli Lilly ... AZN ) today announced that they have entered ... and preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint ... Lilly,s VEGF Receptor 2 antiangiogenic cancer medicine. The planned ... patients with advanced solid tumors. The Phase ...
(Date:5/29/2015)... , May 29, 2015  World-renowned prostate surgeon and New ... on the benefit of MR/Ultrasound Fusion-Guided Biopsy for ... Prostate Cancer Center at Lenox Hill Hospital is ... System in New York City . We,ve ... risk prostate cancers. The use of an MRI makes for ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... Mass., April 9, 2008 /PRNewswire-FirstCall/ - Echo,Therapeutics ... results,from its human feasibility study of the ... permeation medium for its,Symphony(TM) tCGM System, a ... development for diabetes home use and hospital ...
... April 8, 2008 The Association,for Professionals in ... L. Stricof, MT, MPH, of Albany, NY, has ... DeMille Achievement Award.,APIC presents the annual award to ... the ideals of Carole DeMille, a pioneer,in infection ...
Cached Medicine Technology:Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 2Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 3Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 4Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 5New York Infection Prevention Expert Named Recipient of Carole DeMille Award 2
(Date:5/29/2015)... John A. Gennaro, FACHE, MBA, MHSA -- Brings ... Veterans Affairs (VA) is pleased to announce the appointment ... the Cincinnati VA Medical Center (CVAMC). Gennaro will oversee ... Veterans annually and an operating budget of over $387 ... two-division campus located in Cincinnati, Ohio and Fort Thomas, ...
(Date:5/29/2015)... Dot Hill can mark one more item off ... Lake Prince Woods retirement community is the oldest woman to ... , “It was great fun!”, she exclaimed. “I’ve always wanted ... to so they thought this would be ok.” , “We put ... wind tunnel,” she described. “I don’t remember it being noisy, ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and her son, yet ... does no wrong. , It’s fitting, then, that her new ... “God Does No Wrong.” It focuses on what happens when ... , “My story has a positive message about channeling the ... something healing,” Howse said. , “God Does No Wrong” immortalizes ...
(Date:5/29/2015)... May 29, 2015 A group of doctors ... joined the national effort to teach this “new math” to ... U.S. have been “sickened” by the recent implementation of Common ... or hate it, Common Core is now a reality in ... Parents are now seeking ways to improve common core ...
(Date:5/29/2015)... 2015 The print component of “Skin ... of approximately 250,000 and an estimated readership of 750,000. ... social media strategy, and across a network of top ... version of the campaign, click here. , ... Inside, the actress, model and producer details her skin ...
Breaking Medicine News(10 mins):Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2Health News:Indoor Skydiving Brings Thrills to Seniors 2Health News:Turning grief from a child’s passing into virtue 2Health News:Doctors Discover a Cure for the Common Core 2
... new type of stem cell discovered in the prostate ... cancer, according to a new study by researchers at ... Medical Center and NewYork-Presbyterian Hospital. Led by Michael ... at Columbia University Medical Center, the researchers found the ...
... 9 /PRNewswire-FirstCall/ - The following two issuers (HTDS) ... that further to their previous news releases announcing their ... OTCBB both issuers have retained an SEC qualified auditor ... firm, Mina Mar Group is providing this notice to ...
... , More than 1.3 million Americans go on ... , WASHINGTON, Sept. 9 Leading opponents of government-run health ... for Policy Analysis (NCPA) and Salem Radio Network delivered the more than ... to Congress at a rally held on Capitol Hill. , , ...
... , , , , ... Education Verification (OEV) Program meets the new CMS requirements for verification calls. ... multiple carriers and a variety of plan types. , , ... enrolled members to confirm their intent to enroll in the plan, ensure ...
... ... Cell and Drug DevelopmentTM" including products for use in cancer stem cell research. ... newly developed drugs that block a biological pathway (hedge hog) that drives the proliferation ... ...
... , , ROCHESTER, ... Innovation will host Transform, a collaborative symposium on innovations ... http://centerforinnovation.mayo.edu/transform . Transform will feature nationally recognized ... in health care delivery models, including Web-based tools. The ...
Cached Medicine News:Health News:New type of adult stem cells found in the prostate may be involved in prostate cancer development 2Health News:Hard to Treat Diseases, Inc. (HTDS) and Landstar Inc (LDSR) Retain Auditors 2Health News:Hard to Treat Diseases, Inc. (HTDS) and Landstar Inc (LDSR) Retain Auditors 3Health News:National Center for Policy Analysis and Salem Radio Network Deliver Million-Plus Signature Petition Opposing Government Run Health Care 2Health News:National Center for Policy Analysis and Salem Radio Network Deliver Million-Plus Signature Petition Opposing Government Run Health Care 3Health News:DSS Research Announces Outbound Education and Verification Program Meets New CMS Requirements 2Health News:Vitro's Cancer Stem Cell Therapy Complements New Hedge Hog Drugs 2Health News:Vitro's Cancer Stem Cell Therapy Complements New Hedge Hog Drugs 3Health News:Vitro's Cancer Stem Cell Therapy Complements New Hedge Hog Drugs 4Health News:Mayo Clinic Center for Innovation Collaborative Symposium on Innovations in Health Care Experience 2Health News:Mayo Clinic Center for Innovation Collaborative Symposium on Innovations in Health Care Experience 3Health News:Mayo Clinic Center for Innovation Collaborative Symposium on Innovations in Health Care Experience 4
... As the cornerstone of the revolutionary ... N-595 Pulse Oximeter combines Nellcor's best-in-class ... monitoring platform. The motion-tolerant OxiMax N-595 ... most advanced signal processing technology, which ...
The Model 340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
A pocket-sized pulse oximeter. Perfect for the physician's office, emergency medicine, hospitals and clinics, and home health care....
... The Autocorr Pulse Oximeter with SAC ... unique patented software to extract SpO 2 ... in a new way. This cost-effective ... study functions as standard features, and a ...
Medicine Products: